Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells

L. Allegri, F. Baldan, C. Mio, C. Puppin, D. Russo, V. Kryštof, G. Damante,

. 2016 ; 35 (4) : 2413-8. [pub] 20160205

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000452

Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000452
003      
CZ-PrNML
005      
20170118115846.0
007      
ta
008      
170103s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2016.4614 $2 doi
024    7_
$a 10.3892/or.2016.4614 $2 doi
035    __
$a (PubMed)26884249
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Allegri, Lorenzo $u Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy. $7 gn_A_00004430
245    10
$a Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells / $c L. Allegri, F. Baldan, C. Mio, C. Puppin, D. Russo, V. Kryštof, G. Damante,
520    9_
$a Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.
650    _2
$a 2-aminopurin $x analogy a deriváty $x farmakologie $7 D015075
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $7 D000971
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a synergismus léků $7 D004357
650    _2
$a epitelo-mezenchymální tranzice $x účinky léků $7 D058750
650    _2
$a everolimus $x farmakologie $7 D000068338
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a anaplastický karcinom štítné žlázy $x farmakoterapie $x genetika $7 D065646
650    _2
$a nádory štítné žlázy $x farmakoterapie $x genetika $7 D013964
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Baldan, Federica $u Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy.
700    1_
$a Mio, Catia $u Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy.
700    1_
$a Puppin, Cinzia $u Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy.
700    1_
$a Russo, Diego $u Department of Health Sciences, University 'Magna Graecia' of Catanzaro, Catanzaro, Italy.
700    1_
$a Kryštof, Vladimir $u Laboratory of Growth Regulators, Center of the Region Haná for Biotechnological and Agricultural Research, Palacký University and Institute of Experimental Botany AS CR, CZ-77111 Olomuc, Czech Republic.
700    1_
$a Damante, Giuseppe $u Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy.
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 35, č. 4 (2016), s. 2413-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26884249 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170118115953 $b ABA008
999    __
$a ok $b bmc $g 1179592 $s 961019
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 4 $d 2413-8 $e 20160205 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options